{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:35:12Z","timestamp":1793039712061,"version":"4.5.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.7934","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T04:27:47Z","timestamp":1618892867000},"page":"e217934","source":"Crossref","is-referenced-by-count":53,"title":["Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon"],"prefix":"10.1001","volume":"4","author":[{"given":"Ilana D.","family":"Breen","sequence":"first","affiliation":[{"name":"Department of Dermatology, Mayo Clinic Arizona, Scottsdale"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin M.","family":"Brumfiel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic Arizona, Scottsdale"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera H.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic Arizona, Scottsdale"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Butterfield","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Mayo Clinic Arizona, Scottsdale"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana H.","family":"VanderPluym","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic Arizona, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leroy","family":"Griffing","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Mayo Clinic Arizona, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Pittelkow","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic Arizona, Scottsdale"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Mangold","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic Arizona, Scottsdale"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"issue":"8","key":"zoi210252r1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11940-017-0463-4","article-title":"Anti-CGRP monoclonal antibodies: the next era of migraine prevention?","volume":"19","author":"Tso","year":"2017","journal-title":"Curr Treat Options Neurol"},{"issue":"4","key":"zoi210252r2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jaad.2008.06.004","article-title":"Raynaud\u2019s phenomenon: pathogenesis and management.","volume":"59","author":"Bakst","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"8863","key":"zoi210252r3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/0140-6736(93)91286-U","article-title":"Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud\u2019s phenomenon.","volume":"342","author":"Bunker","year":"1993","journal-title":"Lancet"},{"issue":"3","key":"zoi210252r4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2133.1996.tb16221.x","article-title":"Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud\u2019s phenomenon.","volume":"134","author":"Bunker","year":"1996","journal-title":"Br J Dermatol"},{"issue":"3","key":"zoi210252r5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1684\/ejd.2018.3300","article-title":"Systemic therapy with calcitonin has positive clinical effects on systemic sclerosis in patients with cutaneous manifestations.","volume":"28","author":"Uslu","year":"2018","journal-title":"Eur J Dermatol"},{"issue":"8","key":"zoi210252r6","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/head.v59.8","article-title":"Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists.","volume":"59","author":"Evans","year":"2019","journal-title":"Headache"},{"issue":"6024","key":"zoi210252r7","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1136\/bmj.1.6024.1498","article-title":"Raynaud\u2019s phenomenon as side effect of beta-blockers in hypertension.","volume":"1","author":"Marshall","year":"1976","journal-title":"BMJ"},{"issue":"6","key":"zoi210252r8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMra1507638","article-title":"Raynaud\u2019s phenomenon.","volume":"375","author":"Wigley","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi210252r9","first-page":"485","article-title":"Raynaud\u2019s phenomenon: a proposal for classification.","volume":"10","author":"LeRoy","year":"1992","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"zoi210252r10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jvs.2006.07.037","article-title":"Incidence and natural history of Raynaud phenomenon: a long-term follow-up (14 years) of a random sample from the general population.","volume":"44","author":"Carpentier","year":"2006","journal-title":"J Vasc Surg"},{"issue":"2","key":"zoi210252r11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0889-857X(03)00019-X","article-title":"Management of Raynaud\u2019s phenomenon and digital ischemic lesions in scleroderma.","volume":"29","author":"Hummers","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"zoi210252r12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","article-title":"Raynaud phenomenon and digital ulcers in systemic sclerosis.","volume":"16","author":"Hughes","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"zoi210252r14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/archinte.1984.00350160096017","article-title":"Prevalence of Raynaud\u2019s phenomenon in patients with migraine.","volume":"144","author":"Zahavi","year":"1984","journal-title":"Arch Intern Med"},{"issue":"12 pt 1","key":"zoi210252r15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.7326\/0003-4819-116-12-985","article-title":"Increased prevalence of migraine and chest pain in patients with primary Raynaud disease.","volume":"116","author":"O\u2019Keeffe","year":"1992","journal-title":"Ann Intern Med"},{"issue":"9","key":"zoi210252r16","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.amjcard.2013.01.269","article-title":"Prevalence of migraine and Raynaud phenomenon in women with apical ballooning syndrome (Takotsubo or stress cardiomyopathy).","volume":"111","author":"Scantlebury","year":"2013","journal-title":"Am J Cardiol"},{"issue":"4","key":"zoi210252r17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/ard.48.4.312","article-title":"A study of headaches and migraine in Sj\u00f6gren\u2019s syndrome and other rheumatic disorders.","volume":"48","author":"Pal","year":"1989","journal-title":"Ann Rheum Dis"},{"issue":"21","key":"zoi210252r19","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1212\/WNL.0b013e3181a71220","article-title":"Migraine and cardiovascular disease: possible mechanisms of interaction.","volume":"72","author":"Bigal","year":"2009","journal-title":"Neurology"},{"issue":"9273","key":"zoi210252r20","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/S0140-6736(00)05118-7","article-title":"Raynaud\u2019s phenomenon.","volume":"357","author":"Block","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"zoi210252r21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.5114\/reum.2016.64906","article-title":"Recognizing systemic sclerosis: comparative analysis of various sets of classification criteria.","volume":"54","author":"Romanowska-Pr\u00f3chnicka","year":"2016","journal-title":"Reumatologia"},{"key":"zoi210252r18","volume-title":"Migraine With Aura","author":"Kikkeri","year":"2020"},{"key":"zoi210252r13","unstructured":"US Food and Drug Administration. Clinical\/Statistical Review of Galcanezumab. Accessed September 1, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761063Orig1s000MedR.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2778841\/breen_2021_oi_210252_1618266678.85071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T04:27:54Z","timestamp":1618892874000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2778841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.7934","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]}}}